Abdullah K. Altwairgi

Riyadh, SA 
Riyadh, SA 

Overview

Abdullah Altwairgi practices practicing medicine in Riyadh, Saudi Arabia.

His clinical expertise encompasses Febrile Neutropenia, Astrocytoma, Glioma, and Gliomatosis Cerebri.

He is actively involved in clinical research, co-authoring 14 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Riyadh, Saudi Arabia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
Phase II Study of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma
Phase II Study of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma
Enrollment Status: Completed
Publish Date: August 18, 2017
Intervention Type: Radiation, Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

14 Total Publications

Impact of Germline BRCA Status on Pathologic Complete Response (pCR) and Outcomes in Early TNBC Treated with Pembrolizumab-Based Neoadjuvant Chemotherapy (KEYNOTE-522 Regimen): A Real-World Study.
Impact of Germline BRCA Status on Pathologic Complete Response (pCR) and Outcomes in Early TNBC Treated with Pembrolizumab-Based Neoadjuvant Chemotherapy (KEYNOTE-522 Regimen): A Real-World Study.
Journal: Journal of immunotherapy and precision oncology
Published: March 16, 2026

Frequently Asked Questions about Abdullah K. Altwairgi

Is Abdullah K. Altwairgi a top-rated expert for Febrile Neutropenia?

MediFind is an objective health platform that identifies experts based on real-world data. Abdullah K. Altwairgi is classified as an Experienced expert for Febrile Neutropenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Abdullah K. Altwairgi participate in research or clinical trials?

Yes. Abdullah K. Altwairgi has published 14 articles and abstracts on conditions like Febrile Neutropenia. You can view a list of Abdullah K. Altwairgi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Altwairgi's expertise for a condition
ConditionClose
        View All 8 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile